Krishan Jethwa Profile
Krishan Jethwa

@KrishanJethwa

Followers
4K
Following
6K
Media
364
Statuses
2K

GI Radiation Oncologist | Associate PD @MayoRadOnc @MayoClinic | Passions for #PatientCare, #MedEd, QoL, #PublicHealth, and #ClinicalTrials | Views are my own

Joined October 2016
Don't wanna be here? Send us removal request.
@KrishanJethwa
Krishan Jethwa
2 years
🚨🚨🚨.Rectal Cancer Tweetorial!!. Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management!.#GI24 #GIonc #RadOnc. Thank you @ASCO for the opportunity!🙏🏽. 1/
Tweet media one
Tweet media two
29
242
617
@KrishanJethwa
Krishan Jethwa
7 days
RT @MayoRadOnc: Attention medical students and prospective #radonc applicants!. It is time for the Mayo Rochester Virtual Applicant Meet an….
0
12
0
@KrishanJethwa
Krishan Jethwa
9 days
RT @Advances_ASTRO: Is there a radiographic way to determine liver function deterioration (LFD) after SBRT?. This retrospective study used….
0
7
0
@KrishanJethwa
Krishan Jethwa
9 days
RT @Advances_ASTRO: What features are assoc with LRR in pts w/ early #bcsm after mastectomy?. In this RR (n=257) of pts w/ pT1-2N0-1 Bca s/….
0
5
0
@KrishanJethwa
Krishan Jethwa
15 days
RT @PDBrownOnc: HA-PCI is a standard of care for Small Cell Lung Cancer.· Secondary endpoint positive.· Recommend HA-PCI w/ better cognitiv….
0
22
0
@KrishanJethwa
Krishan Jethwa
16 days
RT @aislingbarryro: #oncoscan @IJROBP .📣Check out our recent review - (Re) defining the role of #RT in #liver and #gallbladder cancers. RT….
0
7
0
@KrishanJethwa
Krishan Jethwa
17 days
RT @NiuSanford: Short course RT > FOLFOX x 3 > brachy (10Gy x 2) in T2-T4, small N+ rectal ca. Organ pres 53%, ~OPRA but << OPERA, likely….
0
37
0
@KrishanJethwa
Krishan Jethwa
23 days
RT @PDBrownOnc: Treating Musculoskeletal pain (OA) with low dose radiotherapy.Is Orthovoltage or Megavoltage better?.Meta-analysis no diff….
0
8
0
@KrishanJethwa
Krishan Jethwa
23 days
RT @FASinicropeMD: Check out our new publication on the use of a CDK2/9 inhibitor for treatment of BRAF mutant colorectal cancer. https://t….
0
5
0
@KrishanJethwa
Krishan Jethwa
23 days
RT @Advances_ASTRO: 🔔On-theme with @ASTRO_org’s 2025 Annual Meeting, we’re calling for 🫵🏽your original work in radiation therapy for benign….
0
4
0
@KrishanJethwa
Krishan Jethwa
24 days
RT @Advances_ASTRO: What factors are associated with #radonc contour/plan revision in stereotactic ☢️(SRS, fSRS, SBRT) cases?. In this sing….
0
3
0
@KrishanJethwa
Krishan Jethwa
28 days
RT @AlexSherryMD: Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca?. Happy to share th….
0
79
0
@KrishanJethwa
Krishan Jethwa
1 month
RT @Advances_ASTRO: This review discusses a rare late effect of ☢️ for #hncsm: hyoid bone osteoradionecrosis (ORN). Of 40 cases identified:….
0
1
0
@KrishanJethwa
Krishan Jethwa
1 month
RT @Advances_ASTRO: Can we safely & effectively add radiation to immunotherapy for patients with hepatocellular carcinoma (HCC) with portal….
0
3
0
@KrishanJethwa
Krishan Jethwa
1 month
RT @OncoThor: Are you an oncologist with interest in GI cancer? If so, are you interested in joining a growing academic GI Oncology practic….
0
13
0
@KrishanJethwa
Krishan Jethwa
2 months
RT @Advances_ASTRO: ❗️Out now: ️. In this Ph II trial (n=26), addition of IO (before, during, after) to definitive….
0
1
0
@KrishanJethwa
Krishan Jethwa
2 months
🚨ACCORD Trial🚨. Resected Extrahepatic CCA or Gallbladder CA. 🔍Randomized. Adjuvant CRT + Camrelizumab.vs.Observation. 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!!. @JAMAOnc
Tweet media one
9
45
105
@KrishanJethwa
Krishan Jethwa
2 months
RT @Advances_ASTRO: ❗️OUT NOW - Dosi predictors of toxicity on PROMETHEUS study ❗️. In ♂️ w/ HR Pca receiving ☢️(46/23 + 19-20/2 SBRT boost….
0
1
0
@KrishanJethwa
Krishan Jethwa
2 months
RT @Advances_ASTRO: Teaching Case: What are the outcomes after SBRT for urothelial ca of a transplanted kidney?. After 13 mo, ☢️(40/5) to t….
0
6
0
@KrishanJethwa
Krishan Jethwa
2 months
RT @5_utr: ❗️ STELLAR-303. zanzalintinib + atezolizumab vs regorafenib in MSS CRC is “positive” for OS. More specific data here is pending….
ir.exelixis.com
The Investor Relations website contains information about Exelixis, Inc.'s business for stockholders, potential investors, and financial analysts.
0
4
0